The fund’s investment objective is to achieve capital growth. The fund will invest in healthcare, medical services and related products and companies on a world wide basis. Investment will be in directly held transferable securities. The fund may also invest in collective investment schemes, warrants and money market instruments.
Name | % Net Assets |
---|---|
Pfizer | 5.6% |
Johnson & Johnson | 5.6% |
Merck & Co | 5.1% |
Roche Holding | 4.6% |
Abbott Laboratories | 3.9% |
GlaxoSmithKline | 3.9% |
Novartis | 3.7% |
UnitedHealth Group | 3.4% |
Sanofi | 2.8% |
Gilead Sciences | 2.7% |
Key | % Net Assets |
---|---|
Pfizer | 5.6% |
Johnson & Johnson | 5.6% |
Merck & Co | 5.1% |
Roche Holding | 4.6% |
Other | 79.1% |
Date | 21-Nov-2024 |
---|---|
NAV | 284.40p |
Currency | GBP |
Change | 3.10p |
% | 1.10% |
YTD change | 12.80p |
YTD % | 4.71% |
Fund Inception | 22/05/2000 |
---|---|
Fund Manager | John Bowler |
TER | 1.68 (15-Feb-2012) |
Minimum Investment | |
---|---|
Initial | £1000 |
Additional | n/a |
Savings | £50 |
Charges | |
---|---|
Initial | n/a |
Annual Mang't | 1.50% |
Exit | n/a |
Name | % |
---|---|
Standard deviation | 0.01 |
Sharpe ratio | -0.04 |
You are here: research